| Literature DB >> 33040420 |
Federico Piñero1,2, Margarita Anders2,3, Ilka F Boin4, Aline Chagas5, Emilio Quiñonez6, Sebastián Marciano7, Mario Vilatobá8, Luisa Santos9, Sergio Hoyos Duque10, Agnaldo Soares Lima11, Josemaría Menendez12, Martín Padilla13, Jaime Poniachik14, Rodrigo Zapata15, Alejandro Soza16, Martín Maraschio17, Ricardo Chong Menéndez18, Linda Muñoz19, Diego Arufe20, Rodrigo Figueroa21, Elaine Cristina de Ataide4, Claudia Maccali5, Rodrigo Vergara Sandoval6, Carla Bermudez7, Luis G Podesta1, Lucas McCormack3, Adriana Varón8, Adrián Gadano6, Juan Mattera5, Federico Villamil6,22, Fernando Rubinstein23, Flair Carrilho5, Marcelo Silva1,2.
Abstract
This study aimed to compare liver transplantation (LT) outcomes and evaluate the potential rise in numbers of LT candidates with hepatocellular carcinoma (HCC) of different allocation policies in a high waitlist mortality region. Three policies were applied in two Latin American cohorts (1085 HCC transplanted patients and 917 listed patients for HCC): (i) Milan criteria with expansion according to UCSF downstaging (UCSF-DS), (ii) the AFP score, and (iii) restrictive policy or Double Eligibility Criteria (DEC; within Milan + AFP score ≤2). Increase in HCC patient numbers was evaluated in an Argentinian prospective validation set (INCUCAI; NCT03775863). Expansion criteria in policy A showed that UCSF-DS [28.4% (CI 12.8-56.2)] or "all-comers" [32.9% (CI 11.9-71.3)] had higher 5-year recurrence rates compared to Milan, with 10.9% increase in HCC patients for LT. The policy B showed lower recurrence rates for AFP scores ≤2 points, even expanding beyond Milan criteria, with a 3.3% increase. Patients within DEC had lower 5-year recurrence rates compared with those beyond DEC [13.3% (CI 10.1-17.3) vs 24.2% (CI 17.4-33.1; P = 0.0006], without significant HCC expansion. In conclusion, although the application of a stricter policy may optimize the selection process, this restrictive policy may lead to ethical concerns in organ allocation (NCT03775863).Entities:
Keywords: allocation; hepatocellular carcinoma; liver transplantation; selection
Mesh:
Year: 2021 PMID: 33040420 DOI: 10.1111/tri.13767
Source DB: PubMed Journal: Transpl Int ISSN: 0934-0874 Impact factor: 3.782